[{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Asan Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Asan Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Asan Medical Center"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"RaQualia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RaQualia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RaQualia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"RaQualia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BRAINTREE LABS \/ Sebela Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Sebela Pharmaceuticals"},{"orgOrder":0,"company":"Sebela Pharmaceuticals","sponsor":"HK inno.N","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sebela Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sebela Pharmaceuticals \/ HK inno.N","highestDevelopmentStatusID":"10","companyTruncated":"Sebela Pharmaceuticals \/ HK inno.N"},{"orgOrder":0,"company":"Carnot Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Carnot Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carnot Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Carnot Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Boryung Pharmaceutical Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Boryung Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Boryung Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"United Italian Trading Corporation","sponsor":"HK inno.N","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SINGAPORE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"United Italian Trading Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"United Italian Trading Corporation \/ HK inno.N","highestDevelopmentStatusID":"15","companyTruncated":"United Italian Trading Corporation \/ HK inno.N"},{"orgOrder":0,"company":"HK inno.N","sponsor":"BRAINTREE LABS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ BRAINTREE LABS","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ BRAINTREE LABS"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Carnot Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ Carnot Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Carnot Laboratories"},{"orgOrder":0,"company":"HK inno.N","sponsor":"United Italian Trading Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ United Italian Trading Corporation","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ United Italian Trading Corporation"},{"orgOrder":0,"company":"HK inno.N","sponsor":"BRAINTREE LABS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Braintree Labs","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Braintree Labs"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Luoxin Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Luoxin Pharmaceutical"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Vimedimex Medi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HK inno.N \/ Vimedimex Medi Pharma","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Vimedimex Medi Pharma"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Eurofarma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"HK inno.N \/ Eurofarma","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Eurofarma"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Kim Young Sung","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Kim Young Sung","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Kim Young Sung"}]

Find Clinical Drug Pipeline Developments & Deals for Tegoprazan

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Study Phase : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : PCAB (tegoprazan) is a potassium-competitive acid blocker that reversibly blocks gastric acid secretion by competitively binding with potassium to the proton pumps present in gastric wall cells.

                          Product Name : PCAB

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 17, 2025

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          02

                          Bio-Europe Autumn
                          Not Confirmed
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.

                          Product Name : K-CAB

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 17, 2025

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Dr. Reddy\'s Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Bio-Europe Autumn
                          Not Confirmed
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.

                          Product Name : K-CAB

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 08, 2025

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : BRAINTREE LABS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Bio-Europe Autumn
                          Not Confirmed
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.

                          Product Name : K-CAB

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 07, 2025

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Carnot Laboratories

                          Country arrow
                          Bio-Europe Autumn
                          Not Confirmed

                          Carnot Laboratories

                          Country arrow
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : Tegoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Gastroesophageal Reflux.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 27, 2025

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Bio-Europe Autumn
                          Not Confirmed
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : Tabuk has the exclusive rights for commercialization and marketing of K-CAB (tegoprazan), a novel potassium-competitive acid blocker, to include additional six countries in the MENA region.

                          Product Name : K-CAB

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          May 07, 2025

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Tabuk Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Bio-Europe Autumn
                          Not Confirmed
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : BLI5100 (tegoprazan) is a novel agent and member of a class of oral medications known as P-CABs. It is being evaluated in late-stage clinical trial studies for the treatment of GERD.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 23, 2025

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : HK inno.N

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Bio-Europe Autumn
                          Not Confirmed
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : Tegoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 19, 2024

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Kim Young Sung

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Bio-Europe Autumn
                          Not Confirmed
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.

                          Product Name : K-CAB

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Dr. Reddy\'s Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Bio-Europe Autumn
                          Not Confirmed
                          Bio-Europe Autumn
                          Not Confirmed

                          Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.

                          Product Name : K-CAB

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 27, 2024

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank